Evidence map›Paper›PMID 34120149›Full record

Trial reportTranslational psychiatry2021

Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial.

Erica N Grodin, Spencer Bujarski, Brandon Towns, Elizabeth Burnette, Steven Nieto, Aaron Lim, Johnny Lin, Karen Miotto, Artha Gillis, Michael R Irwin and 2 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Erica N GrodinDepartment of Psychology, University of California at Los Angeles, Los Angeles, CA, USA.ORCID 0000-0001-5528-4918
Spencer BujarskiDepartment of Psychology, University of California at Los Angeles, Los Angeles, CA, USA.
Brandon TownsDepartment of Psychology, University of California at Los Angeles, Los Angeles, CA, USA.
Elizabeth BurnetteDepartment of Psychology, University of California at Los Angeles, Los Angeles, CA, USA.
Steven NietoDepartment of Psychology, University of California at Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-1158-5211
Aaron LimDepartment of Psychology, University of California at Los Angeles, Los Angeles, CA, USA.
Johnny LinInstitute for Digital Research and Education, University of California at Los Angeles, Los Angeles, CA, USA.
Karen MiottoDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA.
Artha GillisDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA.
Michael R IrwinDepartment of Psychology, University of California at Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-1502-8431
Christopher EvansDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA.
Lara A RayDepartment of Psychology, University of California at Los Angeles, Los Angeles, CA, USA. lararay@psych.ucla.edu.ORCID 0000-0002-5734-9444
University of California, Los Angeles · US

Funding

The Role of Striosome Neurons in Mediating Opiod RewardP50DA005010 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WALWYN, WENDY M · 1987 to 2021
$30.7M
UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
Clinical Neuroscience of Alcoholism: Integrating Neuroscience and Clinical TrialsK24AA025704 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY · 2018 to 2026
$1.3M
NIAAA NIH HHS K24 AA025704NIDA NIH HHS P50 DA005010NIDA NIH HHS T32 DA024635U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) P50 DA005010-33
6 · The paper itself

Abstract

Ibudilast, a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE)-3, -4, -10, and -11, and macrophage migration inhibitory factor (MIF), shows promise as a novel pharmacotherapy for alcohol use disorder (AUD). However, the mechanisms of action underlying ibudilast's effects on the human brain remain largely unknown. Thus, the current study examined the efficacy of ibudilast to improve negative mood, reduce heavy drinking, and attenuate neural reward signals in individuals with AUD. Fifty-two nontreatment-seeking individuals with AUD were randomized to receive ibudilast (n = 24) or placebo (n = 28). Participants completed a 2-week daily diary study during which they filled out daily reports of their past day drinking, mood, and craving. Participants completed an functional magnetic resonance imaging (fMRI) alcohol cue-reactivity paradigm half-way through the study. Ibudilast did not have a significant effect on negative mood (β = -0.34, p = 0.62). However, ibudilast, relative to placebo, reduced the odds of heavy drinking across time by 45% (OR = 0.55, (95% CI: 0.30, 0.98)). Ibudilast also attenuated alcohol cue-elicited activation in the ventral striatum (VS) compared to placebo (F(1,44) = 7.36, p = 0.01). Alcohol cue-elicited activation in the VS predicted subsequent drinking in the ibudilast group (F(1,44) = 6.39, p = 0.02), such that individuals who had attenuated ventral striatal activation and took ibudilast had the fewest number of drinks per drinking day in the week following the scan. These findings extend preclinical and human laboratory studies of the utility of ibudilast to treat AUD and suggest a biobehavioral mechanism through which ibudilast acts, namely, by reducing the rewarding response to alcohol cues in the brain leading to a reduction in heavy drinking.

Indexed as

AlcoholismCuesAlcohol DrinkingCravingHumansIndolizinesMagnetic Resonance ImagingPyrazolesPyridinesibudilastIndolizinesPyrazolesPyridines

Identifiers

PMID34120149
PMCPMC8197758
OpenAlexW3170101799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.